Navigation Links
Fluidigm Due Diligence: Company SWOT Analysis and Market Opportunity 2012
Date:3/11/2013

DUBLIN, March 11, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Fluidigm Due Diligence: Company SWOT Analysis and Market Opportunity" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

In this report, we review Fluidigm's historical financial performance, and forecast Fluidigm's product revenues (2012E-2015F) by platform (BioMark / BioMark HD, EP1, Access array, C1 single cell AutoPrep system [to be launched] and TOPAZ). Overall, we believe the company will grow at >25% p.a. until 2015 and reach revenues in excess of $100M. The majority of this growth is expected to be driven by continued placement of BioMark systems, especially for single-cell analysis. By the end of 2011, the company reported that >80 BioMark systems were being used for single-cell analysis. We expect this number to grow to 250-300 instruments by 2015.

In addition, this report provides an overview of the genomics and molecular diagnostics (MDx) spaces in which Fluidigm participates. We review the market growth and trends of both genomics and MDx by technology. The WW genomics market was estimated at -$6.8B in 2011, and forecasted to grow at -6% p.a. Fluidigm focuses on sub-segments of this market, at a specific throughput and plex-level. In addition, Fluidigm addresses three segments within this market: NGS sample preparation, single cell genomics and dPCR. We estimate the current (2011) and future (2015) market size for each of these niche segments.

We also provide an overview of the competitive landscape, with a key focus on dPCR, for which we provide a profile of 7 key competitors.

This report is based on an extensive review of Fluidigm's filings, publications and earning ca
'/>"/>

SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Accordant Health Services, a CVS Caremark Company, Receives URAC Case Management Accreditation
2. Endo Health Solutions to Present at the Cowen and Company 33rd Annual Health Care Conference
3. Auxilium Pharmaceuticals, Inc. to Present at the Cowen and Company 33rd Annual Healthcare Conference
4. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
5. Amgen To Present At The Cowen and Company 33rd Annual Health Care Conference
6. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
7. PrimerLife.com, a Skolkovo Participant Company, Celebrates Anniversary of DNA Discovery with Launch of New Social Network
8. Collegium Pharmaceuticals CEO to Present at the Cowen & Company 33rd Annual Health Care Conference in Boston on March 6, 2013
9. Vanda Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
10. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
11. Neurocrine Biosciences To Present At The Cowen And Company 33rd Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015  Profil Institute for ... on diabetes and obesity, announced today a new textbook,  ... Development,  published by Springer, a leading global scientific publisher. ... analyze and illustrate techniques for use in early phase ...
(Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has announced the addition ... & by End User - Global Forecast to 2019" ... diagnostics market is valued at $1,228.58 million in 2014 and ... reach $2,230.72 million by 2019. Allergy diagnostics is used to ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... Oct. 15 /PRNewswire-FirstCall/,-- Lexicon Pharmaceuticals, Inc. (Nasdaq: ... clinical trial results for LX1031 at the ... in Philadelphia, Pennsylvania. The,studies demonstrated that LX1031 ... that exposure levels in blood were low. ...
... control in patients with type ... has been accepted for publication, OWINGS MILLS, Md., Oct. ... a study conducted by researchers at the,Johns Hopkins University Bloomberg ... peer-reviewed journal which is scheduled for,release in an early 2008 ...
Cached Medicine Technology:Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome 2Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome 3Medifast, Inc. Announces Acceptance for Publication of Clinical Efficacy Study 2
(Date:1/22/2015)... City, Florida (PRWEB) January 22, 2015 IsoComforter, ... cold therapy machine with patented IsoTube design to treat specific ... has introduced the most progressive and easy to use patented ... treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... component of overall health care gains momentum worldwide, Rev. ... York-based HealthCare Chaplaincy Network (HCCN), will be the ... advance spiritual care in Israel’s public health system. , The ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a ... insurance policy . , Some types of vehicles cannot be ... newly released blog post to see if their vehicle qualifies for ... are some of the cars that cannot be covered by a ...
(Date:1/22/2015)... VA (PRWEB) January 22, 2015 Step ... power at the Science Museum of Virginia. Wicked Plants, ... , Wicked Plants unearths 75 poisonous, carnivorous and diabolical ... through each room to uncover the biochemical, physical and ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... challenges in managing their blood glucose levels, and it ... system providing continuous real-time glucose readings. Today, The Endocrine ... on settings where patients are most likely to benefit ... way to self-check blood glucose levels is to prick ...
... caught in its early stages, prostate cancer is treatable ... threshold, the disease becomes largely resistant to current treatments. ... of cancer biologists $9.55 million over five years to ... progresses to the therapy-resistant state. The Program Project ...
... Netherlands, 11 October 2011 Alzheimer,s disease (AD) is ... the world. A new supplement to the ... clearly shows that multiple imaging systems are now available ... "Alzheimer,s disease is now seen as a ...
... published in the October issue of the Journal of ... breast malignancies accounting for 0.5 to one percent of all ... patients. Population-based estimates indicate that the incidence of malignant phyllodes ... frequencies in Hispanic women. Previous studies have focused on ...
... the start of 2011, the active ingredient ticagrelor can ... (ASA) to avoid blood clots in patients with acute ... Quality and Efficiency in Health Care (IQWiG) has now ... coronary syndrome (ACS) in comparison with conventional drugs. This ...
... team of researchers, Gloria Petersen, Ph.D. , of ... California, San Francisco, and Susan Wolf, J.D., of the University ... the National Cancer Institute and the National Human Genome Research ... genetic research results, such as DNA test results, from tissue ...
Cached Medicine News:Health News:Experts find continuous glucose monitoring beneficial in maintaining target blood glucose levels 2Health News:$9.55 million NCI grant targets the resistance of advanced prostate cancer 2Health News:Advances in brain imaging can expedite research and diagnosis in Alzheimer's disease 2Health News:Advances in brain imaging can expedite research and diagnosis in Alzheimer's disease 3Health News:Hispanic women have higher incidence of rare breast tumor 2Health News:Ticagrelor: Considerable added benefit for specific patients 2Health News:Ticagrelor: Considerable added benefit for specific patients 3Health News:Ticagrelor: Considerable added benefit for specific patients 4